Context Therapeutics Inc is trading 5.2% up at $0.63 as shares see a modest rebound following several days of heavy losses linked to clinical trial results.
- The stock experienced a roughly 59% decline over the previous three sessions after investors reacted negatively to interim Phase 1 data for CTIM-76, the company's lead ovarian cancer drug candidate.
- Today's price action appears to reflect short-term stabilization and bargain-hunting, with no fresh company-specific news reported on June 18.